Press Releases Archives Public Relations Contacts	Font Size:   May 8, 2008   ABILIFY® (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia   May 8, 2008   U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features   March 10, 2008   Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex   December 21, 2007   New Drug Application for Tolvaptan, Otsuka’s Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration   December 17, 2007   Otsuka Pharmaceutical, Co., Ltd. Acquires Rights to IV Busulfex from PDL Biopharma, Inc.   September 19, 2007   ECLIPSE Data on Effects of Otsuka’s Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients’ Hemodynamics and Urine Output Featured in Heart Failure Society of America’s Late Breaking Trials
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989